

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) announces that Dr. LIU Ta-pei (“**Dr. LIU**”) has tendered his resignation as an independent non-executive Director (the “**INED(s)**”), a member of the audit committee (the “**Audit Committee**”), the remuneration committee (the “**Remuneration Committee**”) and the nomination committee of the Company (the “**Nomination Committee**”), with effect from 3 August 2023 due to his other personal engagements. Dr. LIU has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Dr. LIU for his valuable contribution to the Company during his tenure of office.

Following the resignation of Dr. LIU with effect from 3 August 2023, and that of Mr. LAM Kit Sun (“**Mr. LAM**”) as disclosed in the announcement of the Company dated 16 May 2023, the Company only has one INED and there are vacancies in the positions of the INEDs, the members of the Audit Committee, the Remuneration Committee and the Nomination Committee and the chairperson of the Nomination Committee respectively. Thus, the number of the INEDs falls below (i) the minimum number of three INEDs required under Rule 5.05(1) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”); (ii) the minimum number of one-third of the Board required under Rule 5.05A of the GEM Listing Rules; and (iii) the minimum number of three members of the audit committee required under Rule 5.28 of the GEM Listing Rules. The Company fails to meet the

requirement that the remuneration committee must be comprising a majority of independent non-executive directors under Rule 5.34 of the GEM Listing Rules. The Company also fails to meet the requirement that the nomination committee must be chaired by the chairman of the board or an independent non-executive director and comprising a majority of independent non-executive directors under Rule 5.36A of the GEM Listing Rules.

To comply with Rules 5.05(1), 5.05A, 5.28, 5.34 and 5.36A of the GEM Listing Rules, the Company is endeavouring to identify suitable candidates to fill the vacancies of the INEDs, the members of the Audit Committee, the Remuneration Committee and the Nomination Committee and the chairperson of the Nomination Committee as soon as practicable, with the relevant appointment(s) to be made within three months from the date of the resignation of Mr. LAM as required under Rules 5.06, 5.33 and 5.36 of the GEM Listing Rules. The Company will make further announcement(s) as and when appropriate.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 3 August 2023

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence as independent non-executive Director.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at <https://www.hkgem.com> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.